Sanjay Shukla - 05 Jan 2024 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
President and CEO, Director
Signature
/s/ Nancy E. Denyes, attorney-in-fact
Issuer symbol
LIFE
Transactions as of
05 Jan 2024
Transactions value $
$0
Form type
4
Filing time
09 Jan 2024, 19:35:28 UTC
Previous filing
12 Dec 2023
Next filing
06 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Employee Stock Option (right to buy) Award $0 +600,000 $0.000000 600,000 05 Jan 2024 Common Stock 600,000 $1.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 5, 2024, such that this option will be fully exercisable on January 5, 2028. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.